This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Biswas, A. K Articles by Sommerauer, J. F Search for Related Content PubMed PubMed Citation Articles by Biswas, A. K Articles by Sommerauer, J. F Social Bookmarking                         What's this?

Aprotinin in the management of life-threatening bleeding during extracorporeal life support

Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children’s Medical Center of Dallas and the University of Texas Southwestern Medical Center, Dallas, Texas, akbiswas{at}pnh10.med.navy.mil

Leslie Lewis

Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children’s Medical Center of Dallas and the University of Texas Southwestern Medical Center, Dallas, Texas

John F Sommerauer

Division of Pediatric Critical Care Medicine, Department of Pediatrics, Children’s Medical Center of Dallas and the University of Texas Southwestern Medical Center, Dallas, Texas

Contact with the synthetic surfaces of an extracorporeal circuit induces alterations in vascular components, derangements of the coagulation cascade and a systemic inflammatory response. Aprotinin reduces intraoperative and postoperative bleeding in adults undergoing cardiopulmonary bypass; however, trials in children have not had similar favorable results. While there have been some anecdotal reports, there have been no prospective clinical trials exploring the utility of aprotinin in the prevention of or as a therapy for bleeding while on extracorporeal life support (ECLS). We present a case series on our experience utilizing aprotinin for the treatment of life-threatening bleeding during ECLS. The combination of a loading dose followed by a continuous infusion resulted in significant reduction in blood loss and blood product utilization. This suggests that aprotinin may have clinical efficacy in the management of massive blood loss while on ECLS; however, larger controlled trials will be essential to determine the efficacy and appropriate dosing regimens before widespread use in ECLS can be advocated.

Perfusion, Vol. 15, No. 3, 211-216 (2000)
DOI: 10.1177/026765910001500305


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?